UCB (STU:UNC) Other Current Payables: €2,105 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
91 GF Score
Price €236.80
GF Value €211.61
Valuation Modestly Overvalued
View Full Analysis

What is UCB Other Current Payables?

UCB STU:UNC +0.38% 91 Other Current Payables is €2,105 Mil as of Dec. 2025. GuruFocus rates STU:UNC with a GF Score™ of 91/100 and a GF Value™ of €211.61 (Modestly Overvalued).

UCB's Other Current Payables for the quarter that ended in Dec. 2025 was €2,105 Mil.

UCB's quarterly Other Current Payables declined from Dec. 2024 (€1,449 Mil) to Jun. 2025 (€0 Mil) but then increased from Jun. 2025 (€0 Mil) to Dec. 2025 (€2,105 Mil).

UCB's annual Other Current Payables increased from Dec. 2023 (€1,023 Mil) to Dec. 2024 (€1,449 Mil) and increased from Dec. 2024 (€1,449 Mil) to Dec. 2025 (€2,105 Mil).

UCB Other Current Payables Related Terms

UCB Other Current Payables Historical Data

* Premium members only.

The historical data trend for UCB's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Other Current Payables Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,084.00 1,165.00 1,023.00 1,449.00 2,105.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,023.00 0.00 1,449.00 0.00 2,105.00
STU:UNC
91GF Score
UCB SA STU:UNC
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €2,105 Mil mean?
UCB (STU:UNC) has a Other Current Payables of €2,105 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on UCB and its competitors.
Is UCB's Other Current Payables too high?
UCB's current Other Current Payables is €2,105 Mil. Overall, UCB has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Other Current Payables compare to VRTX and REGN?
UCB's Other Current Payables of €2,105 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on UCB and its competitors. UCB's current Other Current Payables is €2,105 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.61, compared to a current price of €236.80 — trading 11.9% above its estimated fair value. The current Other Current Payables is €2,105 Mil. UCB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For UCB (STU:UNC), the current Other Current Payables is €2,105 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €236.80 is trading 11.9% above its estimated GF Value™ of €211.61. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Other Current Payables: €2,105 Mil
  • GF Value™: €211.61 vs. price of €236.80 (11.9% above fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
91GF Score

Get the complete analysis for STU:UNC

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€236.80
Price
€211.61
GF Value